Core Scientific, Inc/tx Schedule 13G passive stakes

Pentwater Capital Management LP and Matthew Halbower have filed a Schedule 13G, reporting beneficial ownership of 0.4% of Core Scientific, Inc. common stock.

Jericho Capital Asset Management L.P. and Josh Resnick have reported beneficial ownership of 7.2% of Core Scientific, Inc.'s common stock as of June 30, 2026.

Valiant Capital Management, L.P., Valiant Capital Management, LLC, and Christopher R. Hansen have jointly filed a Schedule 13G, reporting beneficial ownership of 5.3% of Core Scientific, Inc. common stock as of June 30, 2026.

Jane Street Group, LLC and its affiliates have reported beneficial ownership of 20,125,585 shares, representing 6.3% of Core Scientific, Inc.'s common stock.

Several Citadel-affiliated entities have reported beneficial ownership of Core Scientific, Inc. common stock, collectively holding approximately 6.5% of the outstanding shares.

Vanguard Capital Management has reported beneficial ownership of 16,196,304 shares, representing 5.09% of the outstanding common stock of Core Scientific Inc.

Jane Street Group, LLC, along with its affiliates, has reported beneficial ownership of 7.5% of Core Scientific, Inc.'s common stock, totaling 23,967,780 shares.

Valiant Capital Management, L.P. and Christopher R. Hansen have reported a 5.1% beneficial ownership stake in Core Scientific, Inc. common stock.

Citadel Securities and affiliated entities have reported a 4.1% beneficial ownership stake in Core Scientific, Inc. common stock.

Multiple entities within the Susquehanna Investment Group have collectively reported beneficial ownership of 4.6% of Core Scientific, Inc. common stock as of March 31, 2025.

Vanguard Portfolio Management has reported beneficial ownership of 18,843,184 shares, representing 5.97% of Core Scientific Inc.'s common stock, as of March 31, 2026.

The Vanguard Group filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Core Scientific Inc. following an internal realignment.

Valiant Capital Management and its affiliates have reported a 5.1% beneficial ownership stake in Core Scientific, Inc., holding over 16.2 million shares.

A group of affiliated Susquehanna entities has reported a collective beneficial ownership of 5.6% in Core Scientific, Inc., totaling 17,376,097 shares.

Barclays PLC has filed an amendment to its Schedule 13G, reporting a passive beneficial ownership of 0.42% in Core Scientific Inc.

Valiant Capital Management, L.P., along with its affiliates, has disclosed a 4.2% beneficial ownership stake in Core Scientific, Inc., totaling 13,120,302 shares of common stock.

The Vanguard Group has disclosed an increased beneficial ownership of 10.95% in Core Scientific Inc., holding 33,960,320 shares of common stock.

Citadel Securities GP LLC, Citadel Securities Group LP, and Kenneth Griffin have disclosed a 5.5% beneficial ownership stake in Core Scientific, Inc. common stock.

Pentwater Capital Management LP and Matthew Halbower have reported a passive 8.5% beneficial ownership stake in Core Scientific, Inc., totaling 26,050,000 shares.

A group of affiliated Susquehanna entities has disclosed a 4.9% beneficial ownership stake in Core Scientific, Inc., held for ordinary business purposes.

Barclays PLC has reported a beneficial ownership of 5.27% in Core Scientific Inc., totaling 16,203,350 common shares.

Valiant Capital Management, L.P., along with its affiliates, has reported a 5.8% beneficial ownership stake in Core Scientific, Inc., holding over 18 million shares.

A group of affiliated broker-dealers, including Susquehanna Investment Group, has disclosed a 6.2% beneficial ownership stake in Core Scientific, Inc.

The Vanguard Group reported a 9.14% beneficial ownership stake in Core Scientific Inc.'s common stock as of June 30, 2025, through an amended Schedule 13G filing.

BlackRock, Inc. has reported a 7.8% beneficial ownership stake in Core Scientific, Inc., holding over 23 million shares of common stock.

Tospring Technology Limited, Bitmain Technologies Holding Limited, and Ketuan Zhan have jointly disclosed a 1.9% beneficial ownership stake in Core Scientific, Inc. as of December 31, 2024.

The Vanguard Group has reported a 6.93% beneficial ownership stake in Core Scientific Inc. as of December 31, 2024, indicating a passive investment position.